Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Alto Neuroscience, Inc. (ANRO) AI Forecast

Our AI analyzed Alto Neuroscience, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$ANRO Neutral Signal Full forecast available
Sign Up Free

Alto Neuroscience, Inc. (ANRO) Stock Forecast 2025

Alto Neuroscience, Inc. (ANRO) AI Stock Price Forecast & Investment Analysis

Alto Neuroscience, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Alto Neuroscience, Inc. (ANRO) - Comprehensive Stock Analysis & Investment Research

Deep dive into Alto Neuroscience, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 9:53 p.m. (UTC)

Alto Neuroscience, Inc. Investment Summary

When evaluating whether Alto Neuroscience, Inc. (ANRO) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Alto Neuroscience, Inc. (ANRO) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $977 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Alto Neuroscience, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Alto Neuroscience, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Alto Neuroscience, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Alto Neuroscience, Inc.

Sign Up Free
Corporate Identity

Alto Neuroscience, Inc. (Stock Symbol: ANRO) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Alto Neuroscience, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Alto Neuroscience, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Alto Neuroscience, Inc....

Unlock Full Company Profile

Get complete details about Alto Neuroscience, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Alto Neuroscience, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Alto Neuroscience, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Alto Neuroscience, Inc....

Unlock Financial Analysis

Get complete financial metrics for Alto Neuroscience, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Alto Neuroscience, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Alto Neuroscience, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Alto Neuroscience, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-63 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 20.52 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Alto Neuroscience, Inc. (ANRO) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Alto Neuroscience, Inc. stock analysis.

Deep dive into Alto Neuroscience, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Alto Neuroscience, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Alto Neuroscience, Inc.:

P/B Ratio 4.01x
Market Cap $977M
EPS $-3.04
Book Value/Share $6.94
FCF/Share $-1.79
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Alto Neuroscience, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Alto Neuroscience, Inc.: An ROE of -22.1% indicates room for improvement in shareholder value creation.

ROE -22.1%
ROA -19.4%
ROIC -21.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Alto Neuroscience, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Alto Neuroscience, Inc.: A current ratio of 20.52 indicates strong liquidity.

Current Ratio 20.52x
D/E Ratio 0.14x
Financial Leverage 1.14x
Interest Coverage -79.4x
Working Capital $256M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Alto Neuroscience, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Alto Neuroscience, Inc.: Free cash flow of $-63M indicates cash challenges that need attention.

Operating Cash Flow -$44M
Free Cash Flow -$63M
Capital Spending -$19M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Alto Neuroscience, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Alto Neuroscience, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Alto Neuroscience, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Alto Neuroscience, Inc.:

Income Statement
Operating Income -$57M
Net Income -$53M
R&D Expense $40M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 269%
Cash & Short-term Investments 264%
Total Liabilities 33%
Short-term Debt 10%
Dividend & Shareholder Information
Shares Outstanding 35M
Growth Metrics (YoY)
EPS Growth -10.9%

Latest Alto Neuroscience, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Alto Neuroscience, Inc. (ANRO) stock price and investment outlook.

📰 Loading...

Alto Neuroscience, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Alto Neuroscience, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $146M x 1.7x
ABBV ██% $454.62B 125.1x x
ABCL ██% $1.60B x 1.7x
ABEO ██% $349M 5.3x 2.4x
ABT ██% $182.14B 29.0x 3.5x
ABUS ██% $869M 5.4x 3.3x
ABVC ██% $26M x 2.4x
ABVX ██% $10.05B x x
ACAD ██% $4.34B 11.6x 3.5x
ACET ██% $79M x 0.6x
ACRS ██% $750M x 5.2x
ACRV ██% $60M x 0.6x
ACUT ██% $4M x x
ACXP ██% $6M x 0.9x
ADAG ██% $233M x 6.2x
ADCT ██% $145M x x
ADIL ██% $6M x 1.7x
ADTX ██% $3M x x
ADXN ██% $7M x x
AEON ██% $11M x x
AGIO ██% $2.19B x 2.0x
AKBA ██% $343M x 12.5x
AKTX ██% $15M x 1.0x
ALDX ██% $96M x 2.3x
ALKS ██% $8.78B 57.5x 5.0x
ALLR ██% $19M x 2.8x
ALMS ██% $3.39B x 6.0x
ALNY ██% $36.85B 117.5x 46.7x
ALT ██% $576M x 2.0x
ALXO ██% $272M x 1.8x
ALZN ██% $5M x 7.0x
AMLX ██% $2.16B x 7.9x
AMPH ██% $856M 10.8x 1.1x
AMRN ██% $290M x 0.6x
AMRX ██% $5.72B 46.8x x
ANAB ██% $1.56B x 122.1x
ANEB ██% $12M x 1.6x
ANIP ██% $1.64B 17.8x 2.9x
ANIX ██% $117M x 8.1x
ANNX ██% $782M x 3.8x
ANRO ██% $977M x 4.0x
ANTX ██% $177M x 2.2x
ANVS ██% $71M x 22.7x
APLM ██% $40M x x
APRE ██% $7M x 0.2x
APUS ██% $9M x 0.1x
APVO ██% $5M x 0.4x
AQST ██% $464M x x
ARCT ██% $164M x 0.9x
ARDX ██% $1.25B x 8.4x
ARQT ██% $3.48B x 18.4x
ARTL ██% $4M x 0.5x
ARVN ██% $530M x 1.4x
ARWR ██% $12.02B x 19.6x
ASBP ██% $9M x 2.3x
ASMB ██% $513M x 2.6x
ASND ██% $15.71B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.65B x 16.6x
ATHE ██% $85M x x
ATNM ██% $28M x 12.1x
ATOS ██% $24M x 0.8x
ATXI ██% $910K x 0.8x
AUPH ██% $1.99B 6.7x 3.5x
AVBP ██% $1.37B x 4.2x
AVIR ██% $386M x 1.7x
AVTX ██% $1.05B x 15.4x
AXIM ██% $1M x x
AXSM ██% $12.42B x 227.5x
AZTR ██% $2M x 0.2x
BBIO ██% $16.23B x x
BBOT ██% $711M x 1.9x
BCAX ██% $1.82B x 3.5x
BCTX ██% $32M x 1.3x
BCYC ██% $290M x 0.5x
BDPT ██% $10K x x
BDRX ██% $2M x x
BFRG ██% $11M x 2.3x
BFRI ██% $13M x 2.1x
BHC ██% $1.72B x x
BHST ██% $45M x 1.8x
BIOA ██% $972M x 2.6x
BIOE ██% $13M 9.7x x
BIOM ██% $510K x x
BIVI ██% $11M x 0.7x
BIXT ██% $3M x x
BLRX ██% $13M x x
BLTE ██% $6.10B x 7.9x
BMEA ██% $91M x 4.9x
BMRN ██% $11.38B 42.3x 1.8x
BMY ██% $125.36B 17.2x 6.3x
BNTC ██% $396M x 2.2x
BOLD ██% $56M x 0.7x
BOLT ██% $7M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $25M x 0.4x
BSPK ██% $10K x x
BTAI ██% $24M x x
BYSI ██% $44M x x
CALC ██% $11M x x
CANF ██% $7M x 1.2x
CAPR ██% $1.14B x 4.1x
CATX ██% $336M x 1.0x
CBIO ██% $629M x 6.2x
CDT ██% $2M x x
CING ██% $62M x 3.3x
CLCS ██% $65M x x
CLNN ██% $65M x x
CLRB ██% $20M x 5.9x
CLSDQ ██% $1M x x
CLYM ██% $731M x 4.9x
CMMB ██% $10M x 0.8x
CMND ██% $2M x x
CMPS ██% $1.58B x 4.8x
CNBX ██% N/A x x
CNSP ██% $8M x 111.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $138M x 3.2x
CNTX ██% $54M x 1.0x
COCP ██% $13M x 3.1x
COGT ██% $6.87B x 11.3x
COLL ██% $1.15B 15.4x 3.7x
CORT ██% $10.09B 213.2x 15.8x
COYA ██% $103M x 2.1x
CPHI ██% $75M x 2.0x
CPIX ██% $102M x 4.7x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $165M x 1.3x
CRMD ██% $631M 3.5x 1.4x
CRNX ██% $8.81B x 6.9x
CRVO ██% $25M x 2.3x
CRVS ██% $1.15B x 4.8x
CTMX ██% $725M x 2.3x
CTNM ██% $537M x 2.2x
CTOR ██% $54M x 1.5x
CTTH ██% $4M x 5.3x
CTXR ██% $14M x 0.2x
CUE ██% $136M x 6.3x
CURX ██% $6M x 0.7x
CVKD ██% $6M x 3.5x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.3x
CYDY ██% $285M x x
CYPH ██% $62M x 0.7x
CYRX ██% $759M 9.5x 1.5x
CYTK ██% $11.12B x x
DARE ██% $18M x 25.0x
DCOY ██% $3M x 0.7x
DERM ██% $180M x 5.8x
DMAC ██% $367M x 7.8x
DMRA ██% $1.83B x 3.6x
DNTH ██% $5.72B x 4.8x
DRMA ██% $5M x 0.8x
DRUG ██% $700M x x
DSGN ██% $726M x 3.3x
DWTX ██% $51M x 0.6x
DYN ██% $3.95B x 4.6x
EBS ██% $388M x 0.7x
EDSA ██% $50M x 4.9x
ELAB ██% $4M x 0.3x
ELAN ██% $12.37B x 1.9x
ELDN ██% $284M x 6.3x
ELTP ██% $409M 9.1x 4.1x
ELTX ██% $83M x x
ELVN ██% $3.77B x 8.3x
EMMA ██% $820K x x
ENLV ██% $73M 0.0x 0.0x
ENSC ██% $4M x x
ENTA ██% $376M x 3.2x
ENVB ██% $5M x 1.1x
EOLS ██% $404M x x
EPRX ██% $412M x 5.0x
EQ ██% $161M x 2.7x
ERAS ██% $6.01B x 15.3x
ERNA ██% $5M x 0.7x
ESPR ██% $799M x x
ETON ██% $1.21B x 39.5x
ETST ██% $35M 7.2x 5.0x
EVFM ██% $1M x x
EVMN ██% $408M x 1.3x
EWTX ██% $4.45B x 9.0x
FBIO ██% $114M 0.9x 0.7x
FBLG ██% $4M x 1.5x
FBRX ██% $1.57B x 37.2x
FHTX ██% $298M x x
FLNA ██% $45M x 0.7x
FTH ██% $716M x x
FULC ██% $250M x 0.8x
GALT ██% $227M x x
GANX ██% $77M x 5.5x
GCAN ██% $260K x x
GDTC ██% $10M x x
GERN ██% $963M x 4.2x
GHRS ██% $1.73B x x
GLMD ██% $3M x 0.2x
GLSI ██% $193M x 36.7x
GNLX ██% $133M x 5.8x
GNPX ██% $4M x 0.2x
GOSS ██% $70M x x
GOVX ██% $4M x 8.9x
GPCR ██% $3.61B x 2.5x
GRCE ██% $39M x 0.6x
GRI ██% $3M x 0.3x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $101.62B x x
GTBP ██% $12M x 1.6x
GYRE ██% $670M x 6.6x
HCM ██% $1.88B 2.1x 1.5x
HCWB ██% $4M x 0.7x
HELP ██% $479M x x
HEPA ██% $1M x 0.7x
HIND ██% $15M x 2.2x
HOOK ██% $14M x 0.4x
HOWL ██% $17M x 1.4x
HRMY ██% $2.07B 14.2x 2.3x
HRTX ██% $87M x 9.6x
HSTC ██% $99M x 79.9x
HURA ██% $137M x 5.9x
HYFT ██% $55M x x
HYPD ██% $40M x 0.7x
IBIO ██% $70M x 0.9x
IBO ██% $46M x 4.0x
IDYA ██% $3.22B x 3.4x
IFRX ██% $255M x x
IGC ██% $27M x 4.4x
IMMP ██% $57M x x
IMMX ██% $626M x 7.4x
IMNM ██% $2.49B x 4.2x
IMNN ██% $6M x 1.8x
IMRN ██% $9M x x
IMRX ██% $284M x 1.4x
IMUX ██% $195M x 1.3x
INBP ██% $5M x 0.3x
INDP ██% $369M x 295.8x
INDV ██% $5.02B 19.9x x
INM ██% $10M x 1.4x
INO ██% $84M x 13.8x
INSM ██% $23.26B x 33.0x
INTI ██% $15M x x
INVA ██% $1.58B 3.1x 1.2x
IOBTQ ██% $70K x 0.1x
IONS ██% $9.27B x 18.9x
IRD ██% $241M x x
IRON ██% $2.87B x 4.2x
IRWD ██% $624M 6.1x x
ISCO ██% $2M x x
IVA ██% $1.07B x x
IXHL ██% $38M x 0.5x
JAGX ██% $5M x x
JANX ██% $957M x 1.0x
JAZZ ██% $15.78B 534.9x 3.5x
JBIO ██% $1.19B x 4.0x
JNJ ██% $624.17B 29.7x 7.4x
JUNS ██% $6M x x
KALA ██% $11M x 1.1x
KALV ██% $1.38B x x
KAPA ██% $6M x 1.2x
KAYS ██% $140K x x
KMDA ██% $401M x x
KNSA ██% $4.82B 66.0x 8.0x
KPRX ██% $10M x 0.7x
KPTI ██% $160M x x
KROS ██% $200M x 0.7x
KRRO ██% $166M x 1.4x
KTTA ██% $16M x 0.3x
KURA ██% $928M x 8.6x
KYNB ██% $29M 0.2x x
LAB ██% $343M 4.4x 0.6x
LBRX ██% $993M x 2.6x
LEGN ██% $4.55B x x
LEXX ██% $14M x 3.0x
LFCR ██% $166M x x
LFVN ██% $79M 10.0x 2.4x
LGND ██% $6.05B 39.4x 6.1x
LGVN ██% $19M x 1.2x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $35M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.85B x x
LLY ██% $1.07T 42.4x 34.4x
LNAI ██% $11M x x
LPCN ██% $16M x 0.7x
LQDA ██% $7.86B 352.5x 72.4x
LRMR ██% $403M x 2.6x
LSTA ██% $19M x 1.8x
LTRN ██% $32M x 9.4x
LXRX ██% $943M x 4.7x
LYEL ██% $298M x 1.1x
MAIA ██% $78M x 2.8x
MANE ██% $4.84B x 12.4x
MBIO ██% $4M x 0.5x
MBRX ██% $16M x 1.0x
MBX ██% $3.02B x 6.9x
MCRB ██% $50M x 1.9x
MDCX ██% $22M x 16.4x
MDGL ██% $12.52B x 23.0x
MGNX ██% $255M x 12.0x
MIRA ██% $39M x 4.2x
MIRM ██% $6.97B x 28.7x
MIST ██% $141M x 3.9x
MLTX ██% $1.62B x 6.4x
MLYS ██% $2.23B x 3.5x
MNKD ██% $1.20B x x
MNOV ██% $64M x 1.6x
MNPR ██% $708M x 5.2x
MPLT ██% $1.59B x 4.0x
MREO ██% $46M x 1.4x
MRK ██% $322.55B 36.1x 7.0x
MRKR ██% $20M x 1.5x
MRVI ██% $2.60B x 12.3x
MSLE ██% $200M x x
MTNB ██% $2M x 0.5x
MTVA ██% $8M x 0.9x
NAMS ██% $3.56B x 5.4x
NATR ██% $360M 18.1x 2.2x
NBP ██% $205M x 0.8x
NBTX ██% $1.91B x x
NCEL ██% $20M x 37.7x
NCNA ██% $6M x x
NERV ██% $195M x x
NEUP ██% $21M x 0.7x
NGNE ██% $710M x 3.0x
NIKA ██% $806M x x
NKTR ██% $2.34B x 4.1x
NKTX ██% $171M x 0.6x
NMAD ██% $89M x 11.2x
NNVC ██% $33M x 3.6x
NRIX ██% $2.46B x 6.1x
NRSN ██% $24M x x
NRXP ██% $176M x x
NSRX ██% $36M x 13.1x
NTHI ██% $90M x x
NUVB ██% $2.25B x 7.0x
NUVL ██% $9.75B x 8.3x
NVCT ██% $635M x 44.7x
NVS ██% $297.94B x x
NWBO ██% $273M x x
NXTC ██% $17M x 0.6x
NXTS ██% $3M x 0.2x
OCUL ██% $1.89B x 3.2x
OGEN ██% $2M x 0.4x
OGI ██% $130M x x
OGN ██% $3.56B 14.5x 3.9x
OKUR ██% $170M x 0.9x
OLMA ██% $1.03B x 2.1x
OMER ██% $740M 8.6x x
ONC ██% $33.90B 66.1x 7.1x
ONCO ██% $3M x 0.3x
ONCY ██% $99M x x
OPK ██% $888M x 0.7x
ORGO ██% $313M 115.0x 1.3x
ORIC ██% $1.13B x 2.7x
ORKA ██% $5.55B x 11.4x
ORMP ██% $170M 1.6x 0.7x
OSTX ██% $61M x x
OTLC ██% $13M x 0.1x
OVID ██% $401M x 2.0x
OWPC ██% $110K x x
PAHC ██% $1.38B 14.5x 3.8x
PBH ██% $2.37B 12.5x 1.3x
PBM ██% $11M x x
PBYI ██% $408M 16.7x 3.2x
PCRX ██% $1.02B 198.4x 1.6x
PCSA ██% $8M x 3.0x
PCYN ██% $2M x 1.0x
PDSB ██% $39M x 10.1x
PEPG ██% $145M x 1.1x
PFE ██% $142.33B 19.0x 1.6x
PGEN ██% $1.97B x 97.4x
PHAT ██% $922M x x
PHIO ██% $12M x 0.8x
PHVS ██% $2.32B x x
PKTX ██% $3M x 10.3x
PLRX ██% $67M x 0.4x
PLYX ██% $100M x 40.2x
PMHS ██% $2M x x
PMN ██% $113M x 1.9x
PMVP ██% $71M x 0.8x
PPBT ██% $1M x x
PPCB ██% $3M x 0.3x
PRAX ██% $8.98B x 6.4x
PRFX ██% $4M x 0.4x
PRGO ██% $1.39B x 0.6x
PRLD ██% $324M x 5.4x
PRPH ██% $840K x 0.1x
PRQR ██% $253M x x
PRTA ██% $453M x 1.5x
PTCT ██% $6.50B x x
PTGX ██% $8.70B x 13.3x
PTIX ██% $420K x x
PTN ██% $14M x 1.4x
PTPI ██% $170K 0.0x 0.1x
PULM ██% $6M x 1.8x
PVCT ██% $26M x x
PVLA ██% $2.05B x 8.8x
PYXS ██% $168M x 5.4x
QNRX ██% $9M x 1.0x
QNTM ██% $21M x x
QTTB ██% $457M 13.7x 9.9x
QUCY ██% $25M x 5.5x
QURE ██% $2.49B x 16.6x
RADX ██% $34M x x
RANI ██% $122M x 4.3x
RAPP ██% $1.98B x 4.2x
RARE ██% $2.66B x x
RCKT ██% $358M x 1.5x
RCUS ██% $3.67B x 7.0x
RDY ██% $9.85B x x
REGN ██% $67.80B 15.3x 2.2x
REVB ██% $4M x 0.3x
RFL ██% $118M x 1.6x
RGBP ██% $80K x x
RIGL ██% $678M 1.9x 1.7x
RKTO ██% $19M x 4.5x
RLMD ██% $546M x 2.5x
RLYB ██% $87M x 1.7x
RMHI ██% $25M x x
RMTI ██% $27M x 0.7x
RNAC ██% $229M x x
RNAZ ██% $7M x 5.5x
RNTX ██% $68M x 5.9x
RNXT ██% $43M x 3.8x
ROIV ██% $25.28B x 5.6x
RPRX ██% $33.99B 41.1x 4.9x
RTEZ ██% $1.93B x x
RVPH ██% $6M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.03B x 57.2x
RZLT ██% $466M x 4.0x
SBFM ██% $3M x 0.1x
SCNX ██% $16M x 0.2x
SCYX ██% $290M x 7.0x
SDEV ██% $30M 0.1x 0.2x
SDGR ██% $1.12B x 3.6x
SEPN ██% $1.50B x 4.0x
SER ██% $31M x 1.8x
SGMT ██% $433M x 4.2x
SHPH ██% $2M x 0.5x
SIGA ██% $228M 11.3x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.14B x 7.4x
SKVI ██% $1M x x
SKYE ██% $24M x 2.6x
SLGL ██% $261M x 11.5x
SLN ██% $541M x 11.0x
SLS ██% $2.24B x 20.8x
SMMT ██% $11.88B x 18.9x
SMNR ██% $157M x x
SNDX ██% $1.90B x 45.6x
SNGX ██% $5M x 1.8x
SNSE ██% $31M x x
SNY ██% $106.10B x x
SPRB ██% $124M x 3.6x
SPRC ██% $3M x x
SPRO ██% $69M 4.5x 1.3x
SPRY ██% $596M x 9.7x
SRPT ██% $1.73B 26.6x 1.2x
STOK ██% $1.89B x 4.8x
STTK ██% $702M x 7.3x
SUPN ██% $2.75B x 2.6x
SVRA ██% $1.16B x 6.6x
SXTP ██% $4M x 0.9x
SYBX ██% $8M x 0.6x
SYRE ██% $7.88B x 11.7x
TAK ██% $55.84B x x
TBPH ██% $870M 7.6x 3.0x
TCRT ██% $5M x 3.5x
TELO ██% $82M x 16.5x
TENX ██% $416M x 3.6x
TEVA ██% $36.16B 23.1x 4.4x
TGTX ██% $8.68B 18.8x 14.9x
TLPH ██% $65M x 3.5x
TLX ██% $3.38B x x
TNGX ██% $4.37B x 11.2x
TNXP ██% $165M x 0.7x
TOVX ██% $10M x 0.7x
TPST ██% $15M x 18.3x
TRDA ██% $236M x 0.9x
TRVI ██% $2.31B x 13.4x
TTRX ██% $243M x 39.7x
TVRD ██% $23M x 1.6x
TVTX ██% $5.27B x 53.4x
TXMD ██% $24M 132.6x 0.9x
TYRA ██% $1.89B x 4.9x
UNCY ██% $131M x 3.5x
UPB ██% $344M x 1.1x
URGN ██% $1.99B x x
UTHR ██% $26.39B 20.5x 4.5x
VBIO ██% $900K x 0.1x
VCNX ██% $3M x x
VERA ██% $2.54B x 5.1x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $4.04B x 8.1x
VNDA ██% $319M x 1.1x
VRCA ██% $87M x 5.4x
VRDN ██% $2.05B x 3.2x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $122.36B 28.2x 6.3x
VSTM ██% $551M x 6.7x
VTGN ██% $9M x 0.2x
VTRS ██% $20.28B x 1.4x
VYNE ██% $17M x 0.7x
WHWK ██% $174M x 1.5x
WVE ██% $1.15B x 2.2x
XBIO ██% $6M x 0.8x
XBIT ██% $69M x 0.5x
XCUR ██% $11M x 5.2x
XENE ██% $6.28B x 4.7x
XERS ██% $1.45B 120.6x 111.3x
XLO ██% $58M x 0.8x
XNCR ██% $1.48B x 2.9x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $2.07B x 6.2x
ZLAB ██% $2.09B x 3.2x
ZNTL ██% $321M x 1.8x
ZTS ██% $32.38B 12.3x 10.0x
ZVRA ██% $571M 4.6x 2.8x
ZVSA ██% $940K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Alto Neuroscience, Inc. Stock Forecast

How accurate are Alto Neuroscience, Inc. stock predictions?

Our AI model shows a 60% Spearman correlation coefficient for ANRO predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Alto Neuroscience, Inc. stock price forecasts?

Our analysis considers Alto Neuroscience, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Alto Neuroscience, Inc. a good investment in 2025?

Based on our AI analysis, Alto Neuroscience, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Alto Neuroscience, Inc. forecasts updated?

Alto Neuroscience, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Alto Neuroscience, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...